中文  English

Tel: +86-431-85262367
Fax: +86-431-85262933
E-mail: xiaocs@ciac.ac.cn
Add: ChangChun. China 吉ICP备06005930号-1

News

Caina Xu's paper in Small

Author:XCS Date:2015-12-16 15:08:29

A pulmonary co-delivery system which can simultaneously deliver doxorubicin (DOX) and Bcl2 siRNA to the lungs provides a promising local treatment strategy for lung cancers. In this study, DOX was conjugated onto polyethylenimine (PEI) by using cis-aconitic anhydride (CA, a pH-sensitive linker) to obtain PEI-CA-DOX conjugate. The PEI-CA-DOX/siRNA complex nanoparticles were formed spontaneously via electrostatic interaction between cationic PEI-CA-DOX and anionic siRNA. The drug release experiment showed that DOX released faster at acidic pH as compared with at pH 7.4. Moreover, PEI-CA-DOX/Bcl2 siRNA complex nanoparticles showed higher cytotoxicity and apoptosis induction in B16F10 cells than those treated with either DOX or Bcl2 siRNA alone. When the co-delivery systems were directly sprayed into the lungs of B16F10 melanoma-bearing mice, the PEI-CA-DOX/Bcl2 siRNA complex nanoparticles exhibited enhanced antitumor efficacy compared with the single delivery of DOX or Bcl2 siRNA. Compared with systemic delivery, most drug and siRNA showed a long-term retention in lungs via pulmonary delivery; and a considerable number of the drug and siRNA accumulated in tumor tissues of lungs, but rarely in normal lung tissues. The PEI-CA-DOX/Bcl2 siRNA complex nanoparticles are promising for treatment of the metastatic lung cancer by pulmonary delivery with low side effects to the normal tissues.

Journal: Small 2015, 11, 4321-4333

Author: Caina Xu, Ping Wang, Jingpeng Zhang, Huayu Tian,* Kinam Park, and Xuesi Chen*

DOI: 10.1002/smll.201501034